Hu Zhou

Department of General Surgery, Chinese Academy of Medical Sciences & Peking Union Medical College

Affiliated withChinese Academy of Medical Sciences & Peking Union Medical College

Research Area

Biography

Hu Zhou has not added Biography.
If you are Hu Zhou and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title	2026

Other Publications

Article	Year
Effects of CD70 and CD11a in immune thrombocytopenia patients. Journal of clinical immunology\| PubMed ID: 21541792	2011
Increased expressions of DNA methyltransferases contribute to CD70 promoter hypomethylation and over expression of CD70 in ITP. Molecular immunology\| PubMed ID: 21550117	2011
CD72 gene expression in immune thrombocytopenia. Platelets\| PubMed ID: 22111667	2012
Elevated interleukin-27 enhances the polarization of Th1/Tc1 cells and the production of proinflammatory cytokines in primary immune thrombocytopenia. Human immunology\| PubMed ID: 22210084	2012
Immune thrombocytopenia in the elderly: clinical course in 525 patients from a single center in China. Annals of hematology\| PubMed ID: 22956151	2012
Telomerase activity increased and telomere length shortened in peripheral blood cells from patients with immune thrombocytopenia. Journal of clinical immunology\| PubMed ID: 23239407	2013
The polymorphisms of tumor necrosis factor-induced protein 3 gene may contribute to the susceptibility of chronic primary immune thrombocytopenia in Chinese population. Platelets\| PubMed ID: 25806576	2016
Chinese guidelines for treatment of adult primary immune thrombocytopenia. International journal of hematology\| PubMed ID: 29619624	2018
Risk stratification and outcomes of intracranial hemorrhage in patients with immune thrombocytopenia under 60 years of age. Platelets\| PubMed ID: 32614630	2021
A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. Journal of hematology & oncology\| PubMed ID: 33632264	2021
Dose tapering to withdrawal stage and long-term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an open-label extension study. Journal of thrombosis and haemostasis : JTH\| PubMed ID: 34821020	2021
Pharmacokinetics, Safety, and Pharmacodynamics of Romiplostim in Chinese Subjects With Immune Thrombocytopenia: A Phase I/II Trial. Clinical pharmacology in drug development\| PubMed ID: 34921514	2022
Developing and validating a mortality prediction model for ICH in ITP: a nationwide representative multicenter study. Blood advances\| PubMed ID: 35679462	2022
2021 Chinese consensus on the diagnosis and management of primary immune thrombocytopenia in pregnancy. Chinese medical journal\| PubMed ID: 35730369	2022
Efficacy, safety and bioequivalence of the human-derived B-domain-deleted recombinant factor VIII TQG202 for prophylaxis in severe haemophilia A patients. Haemophilia : the official journal of the World Federation of Hemophilia\| PubMed ID: 35996199	2022
Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor-naïve patients with myelofibrosis: Results of a phase II trial. American journal of hematology\| PubMed ID: 36054786	2022
Factor IX inhibitors in haemophilia B: A report of National Haemophilia Registry in China. Haemophilia : the official journal of the World Federation of Hemophilia\| PubMed ID: 36163649	2023
Preclinical studies of a factor X activator and a phase 1 trial for hemophilia patients with inhibitors. Journal of thrombosis and haemostasis : JTH\| PubMed ID: 36796484	2023
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study. The Lancet. Haematology\| PubMed ID: 37028433	2023
A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera. Experimental hematology & oncology\| PubMed ID: 37344895	2023
Clinical features and current treatment status of essential thrombocythemia in older adults: a multicenter real-world study in China. Annals of hematology\| PubMed ID: 37354213	2023
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study. American journal of hematology\| PubMed ID: 37470365	2023
A life-threatening bleeding prediction model for immune thrombocytopenia based on personalized machine learning: a nationwide prospective cohort study. Science bulletin\| PubMed ID: 37599175	2023
Romiplostim in primary immune thrombocytopenia that is persistent or chronic: phase III multicenter, randomized, placebo-controlled clinical trial in China. Research and practice in thrombosis and haemostasis\| PubMed ID: 37601010	2023
Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China. Research and practice in thrombosis and haemostasis\| PubMed ID: 37700877	2023
Single-dose rituximab plus glucocorticoid versus cyclophosphamide plus glucocorticoid in patients with newly diagnosed acquired hemophilia A: A multicenter, open-label, randomized noninferio... American journal of hematology\| PubMed ID: 37851608	2024
Efficacy and safety of eltrombopag in the treatment of immune thrombocytopenia patients with hepatitis B virus infection: A prospective, multicenter, single arm, phase II trial. American journal of hematology\| PubMed ID: 37883528	2024
Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment. Journal of hematology\| PubMed ID: 38644985	2024
Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trial. Annals of hematology\| PubMed ID: 38842566	2024
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 stud... The Lancet. Haematology\| PubMed ID: 38885672	2024
Reduced Platelet Activation in Triple-Negative Essential Thrombocythemia Compared with JAK2V617F-Mutated Essential Thrombocythemia. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 39330983	2024
Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa-2b. British journal of haematology\| PubMed ID: 39462216	2024
A proteogenomic analysis of cervical cancer reveals therapeutic and biological insights. Nature communications\| PubMed ID: 39578447	2024
Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study. Blood cancer journal\| PubMed ID: 39695117	2024
Sovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2/3 study. The Lancet. Haematology\| PubMed ID: 39799953	2025
Deep learning HRNet FCN for blood vessel identification in laparoscopic pancreatic surgery. NPJ digital medicine\| PubMed ID: 40312536	2025
Efficacy and safety analysis of China's first 10% IVIg (RonsenGlob) therapy in treating adult ITP. Annals of hematology\| PubMed ID: 40347249	2025
Efficacy and safety of a new 10% intravenous immunoglobulin (IVIG) in Chinese patients with primary immune thrombocytopenia (ITP): a multicenter, single-arm, phase III trial. Clinical and experimental medicine\| PubMed ID: 40353902	2025
Dose-optimised recombinant human thrombopoietin eltrombopag in patients with immune thrombocytopenia: a multicenter, randomised controlled trial (The TE-ITP Study). EClinicalMedicine\| PubMed ID: 40896456	2025
Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial. BMJ (Clinical research ed.)\| PubMed ID: 41120215	2025
Long-term efficacy and safety of ropeginterferon alfa-2b under its HIDAT regimen for the treatment of polycythemia vera. Blood advances\| PubMed ID: 41172233	2026
Development and validation of a surgical tool recognition and localization strategy in robotic surgeries. Journal of robotic surgery\| PubMed ID: 41175306	2025
Chinese guidance for the clinical application of adeno-associated virus vector-based gene therapy for hemophilia B (2025). Blood science (Baltimore, Md.)\| PubMed ID: 41180128	2025
Factor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials. Nature medicine\| PubMed ID: 41266685	2026
Hetrombopag for patients with persistent primary immune thrombocytopenia: a post hoc analysis of a multicenter, randomized phase Ⅲ trial. Research and practice in thrombosis and haemostasis\| PubMed ID: 41368293	2025
Construction and validation of a high-precision annotated dataset for developing intelligent critical vein recognition models in laparoscopic pancreatic surgery. Frontiers in surgery\| PubMed ID: 41704439	2026
Long-term efficacy and safety of low-dose rituximab in immune thrombocytopenia: a multicentre, prospective, open-label, randomised controlled trial. Annals of hematology\| PubMed ID: 41741872	2026